(MedPage Today) -- At least four patients have died following difficulties in switching from a primary controller to a backup for Thoratec's HeartMate II left ventricular assist device (LVAD), the company announced in a safety advisory on Tuesday.
NEW YORK, NY -- (Marketwired) -- 02/07/14 -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of holders of Thoratec Corporation...
Q4 2013 Earnings Call
February 04, 2014 4:30 pm ET
Gerhard F. Burbach - Chief Executive Officer, President and Executive Director
Taylor C. Harris - Chief Financial Officer, Principal...
OKLAHOMA CITY, OK -- (Marketwired) -- 01/28/14 -- On January 24, 2014, a class action lawsuit was filed in the United States District Court for the Northern District of California against Thoratec Corporation (NASDAQ: THOR). The complaint alleges...
By Peter Geschek:
In the third quarter, HeartWare International (HTWR) had better than expected sales of its cardiac pumps and as a result, its share price moved up substantially.
The jump in sales was driven by the widespread acceptance of...
In a report published Friday, Canaccord Genuity analyst Jason R. Mills reiterated a Buy rating and $45.00 price target on Thoratec Corporation (NASDAQ: THOR).
In the report, Canaccord Genuity noted, “The New England Journal of Medicine (NEJM)...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.